From the *Unité de Recherche Clinique Paris Centre, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; †CIC P0901 Mère Enfant, Inserm, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; ‡EA3620, Université Paris Descartes, Sorbonne Paris-Cité; §Unité d'Immunologie et Hématologie Pédiatriques; ¶Urgences Pédiatriques, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; ‖Laboratoire d'Ethique Médicale, Université Paris Descartes, Paris; **Centre d'Examens de Santé de la Caisse Primaire d'Assurance Maladie de la Seine-Saint-Denis, Bobigny; ††Service d'Explorations Fonctionnelles, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; ‡‡INSERM U845, équipe Homéostasie du Phosphate, Université Paris Descartes; §§Pharmacologie, Groupe Hospitalier Broca Cochin Hôtel Dieu; and ¶¶Service de Physiologie et Explorations Fonctionnelles, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.J.-M.T. and M.C. contributed equally to the study.
Pediatr Infect Dis J. 2013 Nov;32(11):1240-4. doi: 10.1097/INF.0b013e3182a735ed.
Vitamin D insufficiency and HIV infection are both risk factors for chronic disorders, so it is important to consider vitamin D status in HIV-infected patients.
We prospectively investigated serum 25-hydroxyvitamin D (25(OH)D) concentrations, determined by radioimmunoassay, in 113 HIV-infected children (age≤24 years) and 54 healthy controls matched for age and phototype. We assessed the prevalence of vitamin D deficiency and insufficiency (VDD and VDI) defined as 25(OH)D titers of <10 ng/mL and between 10 and 30 ng/mL, respectively, and their predictive factors.
The overall prevalence of VDD and VDI was 38.9% and 58.7%, respectively. Mean serum 25(OH)D concentrations were significantly higher in the HIV group than the control group (14.2±6.9 ng/mL vs. 10.4±5 ng/mL, P<0.001). Variables significantly associated with low serum 25(OH)D concentrations in HIV-infected children were dark phototype (P<0.001) and age (r=-0.19, P=0.03). Patients receiving efavirenz had a trend toward lower serum 25(OH)D concentrations (11.1±4.6 ng/mL vs. 14.6±7 ng/mL, P=0.1). Dark phototype was the only independent risk factor for VDD in HIV-infected children (odds ratio=14.6; 95% confidence interval: 2.4-89.9, P=0.004).
VDD and VDI were common in both HIV-infected and control groups, and serum 25(OH)D concentrations were significantly lower in controls than in HIV-infected children.
维生素 D 不足和 HIV 感染都是慢性疾病的危险因素,因此在 HIV 感染者中考虑维生素 D 状态很重要。
我们前瞻性地研究了 113 例 HIV 感染儿童(年龄≤24 岁)和 54 例年龄和肤色相匹配的健康对照者的血清 25-羟维生素 D(25(OH)D)浓度,用放射免疫法测定。我们评估了维生素 D 缺乏和不足(VDD 和 VDI)的患病率,定义为 25(OH)D 滴度<10ng/ml 和 10-30ng/ml 之间,并评估了其预测因素。
VDD 和 VDI 的总患病率分别为 38.9%和 58.7%。HIV 组的血清 25(OH)D 浓度明显高于对照组(14.2±6.9ng/ml 比 10.4±5ng/ml,P<0.001)。与 HIV 感染儿童血清 25(OH)D 浓度低相关的变量有深色肤色(P<0.001)和年龄(r=-0.19,P=0.03)。接受依非韦伦治疗的患者血清 25(OH)D 浓度有降低的趋势(11.1±4.6ng/ml 比 14.6±7ng/ml,P=0.1)。深色肤色是 HIV 感染儿童 VDD 的唯一独立危险因素(比值比=14.6;95%可信区间:2.4-89.9,P=0.004)。
VDD 和 VDI 在 HIV 感染组和对照组中都很常见,且对照组血清 25(OH)D 浓度明显低于 HIV 感染儿童。